Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer
Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer
复制标题
DOI：
10.1093/annonc/mdq443
复制
发表时间：
2011-04-01
影响因子：
50.5
通讯作者：
Sweeney, C. J.
中科院分区：
文献类型：
--
作者：
Flanagan, J.;Gray, P. Kathryn;Sweeney, C. J.
背景资料：代谢综合征（MS）是一组危险因素，包括肥胖和胰岛素抵抗，并与前列腺癌的发展有关。其对雄激素剥夺治疗（ADT）疗效的影响尚未study.Patients和方法：回顾性研究前列腺癌患者从1998年至2005年在肿瘤内科诊所。在开始ADT时评估MS（根据修订的成人治疗组III标准定义）。研究的终点是前列腺特异性抗原（PSA）进展的时间和总生存期（OS）从开始ADT.Results的时间：82例患者接受ADT治疗和数据，以评估MS的存在被确定。MS患者和非MS患者的中位年龄为70岁，49%的患者符合MS标准。MS患者PSA进展的中位时间为16个月，而非MS患者为36个月（P = 0.003）。开始ADT后MS患者的中位OS为36.5个月，而非MS患者为46.7个月（P = 0.061）。结论：初步数据表明，MS是早期发展去势抵抗性前列腺癌的危险因素，并支持对这一发现进行前瞻性评估的必要性。
Background: Metabolic syndrome (MS) is a set of risk factors that includes obesity and insulin resistance and has been implicated in the development of prostate cancer. Its impact on androgen deprivation therapy (ADT) efficacy has not been studied.Patients and methods: Retrospective study of prostate cancer patients seen from 1998 to 2005 in a medical oncology clinic. MS, as defined by modified Adult Treatment Panel III criteria, was assessed at the time of initiation of ADT. The study end points were time to prostate-specific antigen (PSA) progression and overall survival (OS) from time of starting ADT.Results: Eighty-two patients treated with ADT and data to assess for presence of MS were identified. Median age in men with and without MS was 70 years and 49% of the patients evaluated met criteria for MS. Median time to PSA progression for patients with MS was 16 versus 36 months without MS (P = 0.003). The median OS for patients with MS was 36.5 months after commencing ADT compared with 46.7 months for those patients without MS (P = 0.061).Conclusions: This preliminary data suggest that MS is a risk factor for earlier development of castration-resistant prostate cancer and support the need for a prospective evaluation of this finding.